About Palatin Technologies (NYSEAMERICAN:PTN)
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins28.55%
Return on Equity155.80%
Return on Assets27.77%
Miscellaneous
EmployeesN/A
Outstanding Shares195,370,000
Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."
How were Palatin Technologies' earnings last quarter?
Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its quarterly earnings data on Monday, February, 12th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.19. The biopharmaceutical company had revenue of $10.61 million for the quarter. Palatin Technologies had a return on equity of 155.80% and a net margin of 28.55%. During the same quarter in the previous year, the firm posted ($0.06) EPS. View Palatin Technologies' Earnings History.
What price target have analysts set for PTN?
3 brokers have issued twelve-month target prices for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they expect Palatin Technologies' stock price to reach $4.3333 in the next twelve months. View Analyst Ratings for Palatin Technologies.
Are investors shorting Palatin Technologies?
Palatin Technologies saw a decrease in short interest during the month of March. As of March 29th, there was short interest totalling 4,976,943 shares, a decrease of 1.3% from the March 15th total of 5,044,965 shares. Based on an average daily trading volume, of 2,236,366 shares, the days-to-cover ratio is currently 2.2 days. Approximately 2.7% of the company's shares are sold short.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include Golden Star Resources (GSS), SafeStitch Medical (TRXC), Polymet Mining (PLM), Taseko Mines (TGB), BioTime (BTX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Northern Dynasty Minerals (NAK), Corindus Vascular Robotics (CVRS), Evolution Petroleum (EPM), Denison Mines (DNN), Gold Resource (GORO), Klondex Mines (KLDX), VirnetX (VHC), Uranium Energy (UEC), CRH Medical (CRHM), Saga Communications (SGA) and Bluerock Residential (BRG).
Who are Palatin Technologies' key executives?
Palatin Technologies' management team includes the folowing people:
- Dr. John K. A. Prendergast Ph.D., Co-Founder & Non-Exec. Chairman (Age 64)
- Dr. Carl Spana Ph.D., Co-Founder, Pres, CEO & Director (Age 56)
- Mr. Stephen T. Wills CPA, MST, CFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec. (Age 61)
- Burns McClellan, VP of Investor Relations
- Dr. Johna Lucas M.A., M.D., F.A.C.O.G., Chief Medical Officer
Has Palatin Technologies been receiving favorable news coverage?
Media stories about PTN stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Palatin Technologies earned a media sentiment score of 0.07 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Palatin Technologies?
Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Palatin Technologies' stock price today?
One share of PTN stock can currently be purchased for approximately $1.34.
How big of a company is Palatin Technologies?
Palatin Technologies has a market capitalization of $184.13 million.
How can I contact Palatin Technologies?
Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.
MarketBeat Community Rating for Palatin Technologies (PTN)
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Palatin Technologies (NYSEAMERICAN:PTN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Palatin Technologies in the last 12 months. Their average twelve-month price target is $4.3333, suggesting that the stock has a possible upside of 223.38%. The high price target for PTN is $6.00 and the low price target for PTN is $2.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.3333 | $4.00 | $4.00 | $3.75 |
| Price Target Upside: | 223.38% upside | 422.74% upside | 422.74% upside | 514.75% upside |
Palatin Technologies (NYSEAMERICAN:PTN) Consensus Price Target History
Palatin Technologies (NYSEAMERICAN:PTN) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Palatin Technologies (NYSEAMERICAN:PTN) Earnings History and Estimates Chart
Palatin Technologies (NYSEAMERICAN PTN) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/12/2018 | Q2 18 | ($0.18) | $0.01 | | $10.61 million | View | Listen |  |
| 11/13/2017 | Q1 18 | $0.06 | $0.05 | $28.00 million | $26.94 million | View | N/A | |
| 9/25/2017 | Q4 17 | ($0.02) | $0.07 | $18.54 million | $33.90 million | View | N/A | |
| 5/18/2017 | Q3 2017 | $0.10 | ($0.02) | $60.00 million | $10.82 million | View | N/A | |
| 2/9/2017 | Q2 2017 | ($0.07) | ($0.06) | | | View | Listen | |
| 11/15/2016 | Q117 | ($0.08) | ($0.08) | | | View | N/A | |
| 9/20/2016 | Q416 | ($0.08) | ($0.09) | | | View | Listen | |
| 5/17/2016 | Q316 | ($0.08) | ($0.08) | | | View | N/A | |
| 2/16/2016 | Q216 | ($0.07) | ($0.08) | | | View | N/A | |
| 11/12/2015 | Q116 | ($0.08) | ($0.08) | | | View | Listen | |
| 9/21/2015 | Q415 | ($0.06) | ($0.09) | $2.05 million | $12.95 million | View | Listen | |
| 5/13/2015 | Q315 | ($0.04) | ($0.07) | $0.41 million | | View | Listen | |
| 2/13/2015 | Q115 | $0.01 | $0.03 | $5.40 million | $4.90 million | View | N/A | |
| 11/18/2014 | Q1 15 | $0.04 | $0.01 | $9.00 million | $4.93 million | View | N/A | |
| 9/9/2014 | Q4 14 | $0.03 | ($0.04) | | | View | N/A | |
| 5/13/2014 | Q3 | ($0.03) | ($0.01) | $500.00 million | | View | Listen | |
| 2/18/2014 | Q2 2014 | ($0.04) | ($0.03) | | | View | N/A | |
| 11/14/2013 | Q1 | ($0.05) | ($0.04) | | | View | Listen | |
| 10/1/2013 | Q413 | ($0.05) | ($0.04) | | | View | Listen | |
| 5/14/2013 | Q3 2013 | ($0.05) | ($0.04) | $0.0240 million | | View | Listen | |
| 2/14/2013 | Q2 2013 | $0.01 | ($0.02) | | | View | N/A | |
| 11/14/2012 | Q1 2013 | ($0.16) | ($0.09) | | | View | N/A | |
| 9/11/2012 | Q4 2012 | ($0.10) | ($0.14) | | | View | N/A | |
| 5/14/2012 | Q3 2012 | ($0.13) | ($0.17) | | | View | N/A | |
| 2/15/2012 | Q2 2012 | ($0.09) | ($0.08) | | | View | N/A | |
| 11/15/2011 | Q1 2012 | ($0.10) | ($0.10) | | | View | N/A | |
| 9/22/2011 | Q4 2011 | ($0.08) | ($0.13) | | | View | N/A | |
| 5/16/2011 | Q3 2011 | | ($0.11) | | | View | N/A | |
| 2/15/2011 | Q2 2011 | | ($0.09) | | | View | N/A | |
| 11/15/2010 | Q1 2011 | | ($0.39) | | | View | N/A | |
| 9/27/2010 | Q4 2010 | | ($3.95) | | | View | N/A | |
| 5/13/2010 | Q3 2010 | | ($0.20) | | | View | N/A | |
| 2/16/2010 | Q2 2010 | | $0.44 | | | View | N/A | |
| 9/8/2009 | Q4 2009 | | ($0.02) | | | View | N/A | |
| 5/15/2009 | Q3 2009 | $0.20 | $0.01 | | | View | N/A | |
| 2/17/2009 | Q2 2009 | $0.20 | ($0.04) | | | View | N/A | |
| 11/17/2008 | Q1 2009 | | ($0.50) | | | View | N/A | |
| 9/30/2008 | Q4 2008 | | ($0.60) | | | View | N/A | |
| 5/13/2008 | Q3 2008 | ($0.40) | ($0.60) | | | View | N/A | |
| 2/8/2008 | Q2 2008 | ($1.00) | ($0.40) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Palatin Technologies (NYSEAMERICAN:PTN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Palatin Technologies (NYSEAMERICAN PTN) Insider Trading and Institutional Ownership History
Palatin Technologies (NYSEAMERICAN PTN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/4/2015 | Joseph Stanley Hull | Director | Buy | 2,500 | $0.66 | $1,650.00 | 21,500 | |
| 10/2/2015 | Robert K Deveer Jr | Director | Buy | 10,000 | $0.82 | $8,200.00 | 222,393 | |
| 2/26/2014 | Bvf Partners L P/Il | Major Shareholder | Sell | 540,181 | $1.14 | $615,806.34 | | |
| 2/19/2014 | Bvf Partners L P/Il | Major Shareholder | Sell | 305,966 | $1.17 | $357,980.22 | | |
| 3/19/2013 | Alan W Dunton | Director | Buy | 1,000 | $0.58 | $580.00 | | |
| 2/1/2013 | Alan W Dunton | Director | Buy | 2,000 | $0.59 | $1,180.00 | | |
| 1/28/2013 | Robert I Taber | Director | Buy | 5,000 | $0.59 | $2,950.00 | | |
| 12/31/2012 | Carl Spana | CEO | Buy | 10,000 | $0.57 | $5,700.00 | | |
| 12/28/2012 | Stephen T Wills | CFO | Buy | 10,000 | $0.56 | $5,600.00 | | |
| 12/24/2012 | Perry B Molinoff | Director | Buy | 10,000 | $0.61 | $6,100.00 | | |
| 12/14/2012 | Robert K Deveer Jr | Director | Buy | 21,960 | $0.70 | $15,372.00 | | |
| 9/4/2012 | Alan W Dunton | Director | Buy | 1,000 | $0.58 | $580.00 | | |
(Data available from 1/1/2013 forward)
Palatin Technologies (NYSEAMERICAN PTN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Short Interest in Palatin Technologies, Inc. (PTN) Drops By 1.3%
www.americanbankingnews.com - April 11 at 1:41 AM |
 | HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
finance.yahoo.com - April 7 at 5:32 PM |
| HC Wainwright Begins Coverage on Palatin Technologies (PTN)
www.americanbankingnews.com - April 6 at 10:47 AM |
| Palatin Technologies (PTN) Given a $2.00 Price Target at Roth Capital
www.americanbankingnews.com - April 4 at 3:32 PM |
| Palatin Technologies (PTN) Raised to C- at TheStreet
www.americanbankingnews.com - April 3 at 10:40 AM |
 | Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases
www.prnewswire.com - April 3 at 7:51 AM |
| With An ROE Of 242.93%, Has Palatin Technologies Inc’s (NYSEMKT:PTN) Management Done Well?
finance.yahoo.com - March 29 at 10:15 AM |
| Does Poltronic SA.’s (WSE:PTN) PE Ratio Warrant A Buy?
finance.yahoo.com - March 29 at 10:15 AM |
| Palatin Technologies, Inc. (PTN) Short Interest Down 3.9% in March
www.americanbankingnews.com - March 27 at 1:26 AM |
 | Palatin Technologies (PTN) Anounces Submission of Bremelanotide NDA to FDA for Treatment of HSDD in Premenopausal Women
www.streetinsider.com - March 26 at 4:18 PM |
| Does Palatin Technologies Inc’s (NYSEMKT:PTN) PE Ratio Signal A Buying Opportunity?
finance.yahoo.com - March 22 at 9:44 AM |
| Palatin Technologies, Inc. (PTN) Short Interest Update
www.americanbankingnews.com - March 10 at 2:52 AM |
| Palatin Technologies, Inc. (PTN) Sees Large Drop in Short Interest
www.americanbankingnews.com - February 28 at 1:56 AM |
| A Look at AMAG Pharmaceuticals’ Collaborations
finance.yahoo.com - February 16 at 4:13 PM |
| Palatin Technologies (PTN) Posts Earnings Results
www.americanbankingnews.com - February 13 at 11:12 AM |
| Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
www.prnewswire.com - February 12 at 7:43 AM |
| Short Interest in Palatin Technologies, Inc. (PTN) Declines By 6.6%
www.americanbankingnews.com - February 9 at 6:36 PM |
| Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
finance.yahoo.com - February 8 at 5:54 AM |
| Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational ... - PR Newswire (press release)
www.prnewswire.com - February 7 at 6:10 AM |
 | Palatin Technologies Announces First Dosing In Phase 1 Study Of PL-8177
www.nasdaq.com - February 5 at 3:20 PM |
| Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist
finance.yahoo.com - February 5 at 3:20 PM |
| Palatin Technologies, Inc. (PTN) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 24 at 5:40 PM |
| Palatin Technologies, Inc. (PTN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 10 at 6:04 PM |
| Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For ... - PR Newswire (press release)
www.prnewswire.com - January 4 at 10:13 AM |
| Palatin Technologies, Inc. (PTN) Short Interest Up 53.4% in November
www.americanbankingnews.com - December 11 at 8:36 PM |
| Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs - PR Newswire (press release)
www.prnewswire.com - December 11 at 11:00 AM |
| Short Interest in Palatin Technologies, Inc. (PTN) Rises By 1.0%
www.americanbankingnews.com - November 28 at 1:04 AM |
Palatin Technologies (NYSEAMERICAN:PTN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Palatin Technologies (NYSEAMERICAN:PTN) Income Statement, Balance Sheet and Cash Flow Statement
Palatin Technologies (NYSEAMERICAN PTN) Stock Chart for Sunday, April, 22, 2018
Loading chart…
